Cargando…

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients

Detalles Bibliográficos
Autores principales:	Boissard, F, Fournié, J-J, Quillet-Mary, A, Ysebaert, L, Poupot, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635187/ https://www.ncbi.nlm.nih.gov/pubmed/26430726 http://dx.doi.org/10.1038/bcj.2015.74

Ejemplares similares

Nurse-like cells impact on disease progression in chronic lymphocytic leukemia
por: Boissard, F, et al.
Publicado: (2016)

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions
por: Boissard, Frédéric, et al.
Publicado: (2016)

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
por: Cadot, Sarah, et al.
Publicado: (2020)

3R gene expression in chronic lymphocytic leukemia reveals insight into disease evolution
por: Grgurevic, S, et al.
Publicado: (2016)

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
por: Ysebaert, L, et al.
Publicado: (2015)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
por: Betrian, S, et al.
Publicado: (2016)

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
por: Montillo, M, et al.
Publicado: (2017)

An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia
por: Verstraete, Nina, et al.
Publicado: (2023)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
por: Christoforidou, Anna, et al.
Publicado: (2018)

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
por: İskender, Gülşen, et al.
Publicado: (2020)

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection
por: Fiorcari, Stefania, et al.
Publicado: (2021)

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
por: Cafforio, Luciana, et al.
Publicado: (2021)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells
por: Domagala, Marcin, et al.
Publicado: (2021)

Functional assessment of p53 in chronic lymphocytic leukemia
por: Le Garff-Tavernier, M, et al.
Publicado: (2011)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report
por: Cecyn, Karin Zattar, et al.
Publicado: (2021)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status
por: Grgurevic, Srdana, et al.
Publicado: (2018)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
por: Innocenti, Idanna, et al.
Publicado: (2022)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Behçet's disease‐like clinical manifestations of chronic lymphocytic leukemia during good response to ibrutinib
por: Obama, Kosuke, et al.
Publicado: (2023)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
por: Beresford, Rohan, et al.
Publicado: (2019)

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2016)

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
por: Lutz, Mathias, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8vg1o57gm4isdnkp8tt4k20nlj